Because of this expression pattern, CD33-directed therapies are used in malignancies such as chronic myelomonocytic leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia40–42. This evidence concerns the gene CD33 and myelodysplastic syndrome.